424 related articles for article (PubMed ID: 15184602)
1. Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele.
Caselli RJ; Reiman EM; Osborne D; Hentz JG; Baxter LC; Hernandez JL; Alexander GG
Neurology; 2004 Jun; 62(11):1990-5. PubMed ID: 15184602
[TBL] [Abstract][Full Text] [Related]
2. Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment.
Caselli RJ; Reiman EM; Locke DE; Hutton ML; Hentz JG; Hoffman-Snyder C; Woodruff BK; Alexander GE; Osborne D
Arch Neurol; 2007 Sep; 64(9):1306-11. PubMed ID: 17846270
[TBL] [Abstract][Full Text] [Related]
3. Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes: a replication study.
Caselli RJ; Osborne D; Reiman EM; Hentz JG; Barbieri CJ; Saunders AM; Hardy J; Graff-Radford NR; Hall GR; Alexander GE
J Neurol Sci; 2001 Aug; 189(1-2):93-8. PubMed ID: 11535238
[TBL] [Abstract][Full Text] [Related]
4. Preclinical memory decline in cognitively normal apolipoprotein E-epsilon4 homozygotes.
Caselli RJ; Graff-Radford NR; Reiman EM; Weaver A; Osborne D; Lucas J; Uecker A; Thibodeau SN
Neurology; 1999 Jul; 53(1):201-7. PubMed ID: 10408560
[TBL] [Abstract][Full Text] [Related]
5. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.
Devanand DP; Pelton GH; Zamora D; Liu X; Tabert MH; Goodkind M; Scarmeas N; Braun I; Stern Y; Mayeux R
Arch Neurol; 2005 Jun; 62(6):975-80. PubMed ID: 15956169
[TBL] [Abstract][Full Text] [Related]
6. A distinctive interaction between memory and chronic daytime somnolence in asymptomatic APOE e4 homozygotes.
Caselli RJ; Reiman EM; Hentz JG; Osborne D; Alexander GE; Boeve BF
Sleep; 2002 Jun; 25(4):447-53. PubMed ID: 12071547
[TBL] [Abstract][Full Text] [Related]
7. The APOE epsilon4 allele is associated with decline on delayed recall performance in community-dwelling older adults.
O'Hara R; Yesavage JA; Kraemer HC; Mauricio M; Friedman LF; Murphy GM
J Am Geriatr Soc; 1998 Dec; 46(12):1493-8. PubMed ID: 9848808
[TBL] [Abstract][Full Text] [Related]
8. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.
Stonnington CM; Snyder PJ; Hentz JG; Reiman EM; Caselli RJ
J Clin Psychiatry; 2009 Oct; 70(10):1379-84. PubMed ID: 19573495
[TBL] [Abstract][Full Text] [Related]
9. APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging.
Klages JD; Fisk JD; Rockwood K
Dement Geriatr Cogn Disord; 2003; 15(1):1-5. PubMed ID: 12457072
[TBL] [Abstract][Full Text] [Related]
10. APOE-epsilon4 is associated with memory decline in cognitively impaired elderly.
Dik MG; Jonker C; Bouter LM; Geerlings MI; van Kamp GJ; Deeg DJ
Neurology; 2000 Apr; 54(7):1492-7. PubMed ID: 10751265
[TBL] [Abstract][Full Text] [Related]
11. Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes.
Caselli RJ; Dueck AC; Locke DE; Sabbagh MN; Ahern GL; Rapcsak SZ; Baxter LC; Yaari R; Woodruff BK; Hoffman-Snyder C; Rademakers R; Findley S; Reiman EM
Neurology; 2011 Mar; 76(12):1078-84. PubMed ID: 21325652
[TBL] [Abstract][Full Text] [Related]
12. In Thai Nationals, the ApoE4 Allele Affects Multiple Domains of Neuropsychological, Biobehavioral, and Social Functioning Thereby Contributing to Alzheimer's Disorder, while the ApoE3 Allele Protects Against Neuropsychiatric Symptoms and Psychosocial Deficits.
Tangwongchai S; Supasitthumrong T; Hemrunroj S; Tunvirachaisakul C; Chuchuen P; Houngngam N; Snabboon T; Tawankanjanachot I; Likitchareon Y; Phanthumchindad K; Maes M
Mol Neurobiol; 2018 Aug; 55(8):6449-6462. PubMed ID: 29307083
[TBL] [Abstract][Full Text] [Related]
13. APOE E4 status predicts age-related cognitive decline in the ninth decade: longitudinal follow-up of the Lothian Birth Cohort 1921.
Schiepers OJ; Harris SE; Gow AJ; Pattie A; Brett CE; Starr JM; Deary IJ
Mol Psychiatry; 2012 Mar; 17(3):315-24. PubMed ID: 21263443
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal modeling of frontal cognition in APOE ε4 homozygotes, heterozygotes, and noncarriers.
Caselli RJ; Dueck AC; Locke DE; Hoffman-Snyder CR; Woodruff BK; Rapcsak SZ; Reiman EM
Neurology; 2011 Apr; 76(16):1383-8. PubMed ID: 21502596
[TBL] [Abstract][Full Text] [Related]
15. Impact of APOE in mild cognitive impairment.
Farlow MR; He Y; Tekin S; Xu J; Lane R; Charles HC
Neurology; 2004 Nov; 63(10):1898-901. PubMed ID: 15557508
[TBL] [Abstract][Full Text] [Related]
16. Memory complaints and APOE-epsilon4 accelerate cognitive decline in cognitively normal elderly.
Dik MG; Jonker C; Comijs HC; Bouter LM; Twisk JW; van Kamp GJ; Deeg DJ
Neurology; 2001 Dec; 57(12):2217-22. PubMed ID: 11756600
[TBL] [Abstract][Full Text] [Related]
17. Early onset APOE E4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains.
Smits LL; Pijnenburg YA; van der Vlies AE; Koedam EL; Bouwman FH; Reuling IE; Scheltens P; van der Flier WM
Eur Neuropsychopharmacol; 2015 Jul; 25(7):1010-7. PubMed ID: 25891378
[TBL] [Abstract][Full Text] [Related]
18. Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease.
Lim YY; Kalinowski P; Pietrzak RH; Laws SM; Burnham SC; Ames D; Villemagne VL; Fowler CJ; Rainey-Smith SR; Martins RN; Rowe CC; Masters CL; Maruff PT
JAMA Neurol; 2018 Apr; 75(4):488-494. PubMed ID: 29356823
[TBL] [Abstract][Full Text] [Related]
19. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.
Mosconi L; Perani D; Sorbi S; Herholz K; Nacmias B; Holthoff V; Salmon E; Baron JC; De Cristofaro MT; Padovani A; Borroni B; Franceschi M; Bracco L; Pupi A
Neurology; 2004 Dec; 63(12):2332-40. PubMed ID: 15623696
[TBL] [Abstract][Full Text] [Related]
20. [Apolipoprotein E4 and memory decline in the elderly].
Jonker C; Dik MG; van Kamp GJ; Deeg DJ
Tijdschr Gerontol Geriatr; 2000 Oct; 31(5):198-202. PubMed ID: 11064931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
